An overview of KRAS-targeting therapies for colorectal cancer in phase I and II development

KRAS-targeted therapy in CRC is entering a clinically actionable era. Allele-specific inhibitors are likely to find their place in combinations that suppress adaptive bypass (e.g. SOS1/SHP2, MEK/ERK, EGFR) while leveraging immunotherapy or metabolic vulnerabilities. Prospective biomarker integration and resistance-informed trial designs will be decisive in translating early signals into durable patient benefit.